When evaluating CJC-1295 prijs for institutional research, laboratory buyers must look beyond initial cost-per-milligram metrics to assess true chemical value. Authentic analytical purity, verified by HPLC and mass spectrometry, directly dictates trial reproducibility and empirical reliability in preclinical models.
When evaluating CJC-1295 prijs for institutional research, laboratory buyers must look beyond initial cost-per-milligram metrics to assess true chemical value. Authentic analytical purity, verified by HPLC and mass spectrometry, directly dictates trial reproducibility and empirical reliability in preclinical models.
In scientific procurement, the query for cjc 1295 prijs reflects a broader need to balance budgetary constraints with strict analytical standards. The true cost of CJC-1295 is defined by synthesis quality, amino acid sequence integrity, and verified purity levels rather than nominal retail pricing. Low-cost peptides frequently suffer from sequence truncation, unremoved trifluoroacetic acid (TFA) salts, and residual heavy metals, which corrupt cell culture assays and invalidate animal study models.
Principal investigators evaluating CJC-1295 for research should evaluate suppliers based on batch-specific documentation rather than surface price points. High-purity peptides synthesized in GMP-compliant, US-based facilities undergo rigorous purification steps that add production value but eliminate background variables in downstream experimentation. Inspecting our complete catalog of research peptides provides additional context regarding institutional pricing structures and quality assurance protocols across various secretagogue categories.
CJC-1295 is a synthetic 29-amino acid peptide derivative that functions as a tetrasubstituted growth hormone-releasing hormone (GHRH) analog. By substituting specific amino acids at positions 2, 8, 15, and 27, the molecule exhibits enhanced enzymatic stability against dipeptidyl peptidase-IV (DPP-IV) degradation compared to endogenous GHRH (1-29). This structural modification significantly extends its plasma half-life, allowing researchers to study sustained GHRH receptor stimulation.
Preclinical studies suggest that CJC-1295 binds selectively to the GHRH receptor on anterior pituitary somatotrophs. Receptor activation triggers an intracellular cAMP-dependent signaling cascade, promoting the transcription and pulsatile secretion of endogenous growth hormone (GH). In laboratory settings, this activation leads to a downstream increase in insulin-like growth factor 1 (IGF-1) expression, making it a critical tool for investigating cellular regeneration, protein synthesis, and tissue repair pathways. For a deeper breakdown of signaling pathways, explore our comprehensive GHRH analogs overview.
A critical factor influencing CJC-1295 valuation and study design is the presence or absence of the Drug Affinity Complex (DAC). CJC-1295 DAC incorporates a maleimido-propionic acid linker that covalently binds to circulating serum albumin upon administration in animal models. This bioconjugation extends the half-life to several days, maintaining steady basal GH and IGF-1 elevations. In contrast, CJC-1295 No DAC—technically designated as Modified GRF 1-29—lacks this linker, resulting in a half-life of roughly 30 minutes that mimics physiological GH pulses.
Choosing between these variants alters both the experimental framework and the overall material consumption of a trial. While CJC-1295 DAC requires fewer administration intervals in prolonged animal studies, CJC-1295 No DAC is preferred for investigating short-duration GH pulses or acute receptor activation dynamics. Understanding these structural differences prevents costly protocol errors and ensures researchers purchase the precise chemical format required for their hypothesis.
In vitro data and rodent models demonstrate that CJC-1295 maintains the functional physiological feedback loops of the hypothalamic-pituitary-somatotrophic axis while enhancing total hormone output. Because the peptide stimulates endogenous synthesis rather than introducing exogenous GH, non-human primate and murine studies note a preserved balance of somatostatin inhibition mechanisms, preventing total down-regulation of native receptors.
Research focused on metabolic regulation, skeletal muscle hypertrophy, and connective tissue synthesis frequently utilizes CJC-1295 to evaluate accelerated collagen cross-linking and nitrogen retention. Preclinical investigations show that sustained IGF-1 elevation driven by CJC-1295 promotes satellite cell proliferation in damaged muscle tissue. To review published findings and trial methodologies, consult our centralized PX1 research library.
To ensure that CJC-1295 pricing reflects genuine chemical purity, research facilities must verify that every peptide lot is accompanied by independent analytical documentation. Reagent-grade peptides should achieve a minimum purity threshold of 98% as determined by Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC). HPLC chromatograms separate and quantify target peptide sequences from closely related synthesis impurities, such as deletion sequences or stereoisomers.
Electrospray Ionization Mass Spectrometry (ESI-MS) serves as the secondary verification standard, confirming the exact molecular weight of the compound (3,367.97 Da for CJC-1295 without DAC). Without MS validation, optical HPLC peaks cannot definitively prove sequence identity. PX1 Research subjects every batch to independent ISO 17025 accredited laboratory testing, providing fully transparent, lot-specific Certificates of Analysis (COAs) with every shipment.
Endotoxins—lipopolysaccharides (LPS) derived from Gram-negative bacterial cell walls—pose a primary risk to sensitive in vitro and in vivo research. Contaminated peptide preparations induce inflammatory cytokine cascades, macrophage activation, and unpredicted cell death, completely masking the biological effects of GHRH activation.
High-tier CJC-1295 suppliers utilize Chromogenic Reagent Limulus Amebocyte Lysate (LAL) testing to quantify endotoxin levels. PX1 Research mandates strict limits (typically <0.05 EU/mg), ensuring that lyophilized powders introduce zero background toxicity into delicate primary cell cultures or rodent models. This level of quality control justifies a stable price structure by protecting expensive laboratory trials from systemic contamination.
When designing somatotrophic axis protocols, researchers often evaluate CJC-1295 alongside related peptide candidates within the same functional class. Selecting the optimal compound depends on whether sustained exposure or synergistic pulse stimulation is required for the experimental model.
A comparative assessment highlights distinct functional differences among primary secretagogues:
- Sermorelin: The shortest native GHRH fragment (GRF 1-29), exhibiting a rapid clearance rate ideal for studying acute pituitary response.
- Tesamorelin: A stabilized GHRH analog featuring a trans-3-hexenoic acid group, frequently studied for target visceral adipose tissue metabolism.
- Ipamorelin: A selective ghrelin receptor agonist (GHRP) that triggers GH release via a distinct pathway, often paired with CJC-1295 in preclinical synergistic trials.
For a full comparison of these compounds and their respective binding affinities, review our complete growth hormone secretagogues guide.
Maintaining the structural stability of CJC-1295 requires strict adherence to cold-chain handling and proper reconstitution protocols. Lyophilized CJC-1295 should be stored in a dry, dark environment at -20°C prior to reconstitution to prevent hydrolysis or oxidation of sensitive residues.
For laboratory use, reconstitution should be performed using sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile normal saline depending on the assay design. The solvent should be trickled down the glass wall of the vial rather than sprayed directly onto the peptide cake to prevent shear stress degradation. Once reconstituted, liquid aliquots remain stable at 2°C to 8°C for up to 30 days, while long-term liquid storage requires freezing at -80°C to avoid freeze-thaw degradation cycles.
For academic institutions, biotechnology enterprises, and clinical CROs, procuring CJC-1295 involves evaluating wholesale supply stability and batch-to-batch consistency. Inconsistent manufacturing runs create variable baseline data, leading to wasted research capital and unreliable publication results.
PX1 Research maintains robust inventory controls and multi-state fulfillment nodes (shipping same-day Monday through Friday from facilities in California and Arizona). Institutional buyers seeking bulk quantities for multi-stage trials can access dedicated commercial terms and volume tiers through our wholesale lab portal, ensuring uncompromised supply chain transparency and standardized lot purity.
What determines the CJC 1295 prijs for laboratory procurement?
CJC-1295 pricing is primarily determined by HPLC purity levels, mass spectrometry identity confirmation, manufacturing compliance (GMP facilities), lot-specific endotoxin testing, and whether the compound features the Drug Affinity Complex (DAC).
What is the primary operational difference between CJC-1295 DAC and CJC-1295 No DAC?
CJC-1295 DAC incorporates a maleimido-propionic acid linker that binds to serum albumin, extending its biological half-life to several days in animal models. CJC-1295 No DAC (Mod GRF 1-29) lacks this linker and features a half-life of roughly 30 minutes.
How is CJC-1295 purity verified by PX1 Research?
Every lot undergoes independent ISO 17025 laboratory testing using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity quantification and Electrospray Ionization Mass Spectrometry (ESI-MS) for molecular weight confirmation.
Is CJC-1295 approved for human consumption or medical therapy?
No. CJC-1295 is strictly an experimental compound designated exclusively for laboratory research, in vitro cell assays, and preclinical animal studies. It is not for human or veterinary medical use.
What are the recommended storage conditions for lyophilized CJC-1295?
Lyophilized CJC-1295 should be stored at -20°C in a dry, dark environment. Upon reconstitution with sterile bacteriostatic water, liquid solutions should be kept at 2°C to 8°C and used within 30 days.
What endotoxin thresholds are acceptable for CJC-1295 in cell culture research?
PX1 Research enforces strict endotoxin limits (typically under 0.05 EU/mg) verified via LAL chromogenic assays to prevent inflammatory interference in cell culture and animal models.
Why is trifluoroacetic acid (TFA) removal important in CJC-1295 synthesis?
TFA is a reagent used during solid-phase peptide synthesis. If not properly removed during purification, residual TFA salts can induce cellular toxicity and alter pH balance in delicate bioassays.
How does CJC-1295 compare to Sermorelin in research applications?
Both are GHRH analogs, but Sermorelin represents the native 29-amino acid sequence with a short half-life, whereas CJC-1295 features four amino acid substitutions that resist enzymatic breakdown by DPP-IV.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.